Next Article in Journal
Methylomes in Vegans versus Pescatarians and Nonvegetarians
Next Article in Special Issue
Firing up Cold Tumors—Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy
Previous Article in Journal
Interplay between DNA and RNA Modifications: A Constantly Evolving Process
Previous Article in Special Issue
Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology
Open AccessReview

Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review

by 1,2,3,4,*,†, 1,2,3,† and 1,2,3,*
1
Department of Biomedical Sciences, National Chung Cheng University, Min-Hsiung, Chia-Yi 621, Taiwan
2
Epigenomics and Human Disease Research Center, National Chung Cheng University, Min-Hsiung, Chia-Yi 621, Taiwan
3
Center for Innovative Research on Aging Society (CIRAS), National Chung Cheng University, Min-Hsiung, Chia-Yi 621, Taiwan
4
Division of Hematology and Oncology, Department of Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chia-Yi 621, Taiwan
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 11 November 2020 / Revised: 25 November 2020 / Accepted: 30 November 2020 / Published: 4 December 2020
(This article belongs to the Special Issue Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy)
Breast cancer is one of the leading causes of death among cancer patients worldwide. To date, there are several drugs that have been developed for breast cancer therapy. In the 21st century, immunotherapy is considered a pioneering method for improving the management of malignancies; however, breast cancer is an exception. According to the immunoediting model, many immunosuppressive cells contribute to immunological quiescence. Therefore, there is an urgent need to enhance the therapeutic efficacy of breast cancer treatments. In the last few years, numerous combinatorial therapies involving immune checkpoint blockade have been demonstrated that effectively improve clinical outcomes in breast cancer and combining these with methods of targeting epigenetic regulators is also an innovative strategy. Nevertheless, few studies have discussed the benefits of epi-drugs in non-cancerous cells. In this review, we give a brief overview of ongoing clinical trials involving combinatorial immunotherapy with epi-drugs in breast cancer and discuss the role of epi-drugs in the tumor microenvironment, including the results of recent research. View Full-Text
Keywords: immune checkpoint inhibitors; epi-drug; combination therapy; breast cancer immune checkpoint inhibitors; epi-drug; combination therapy; breast cancer
Show Figures

Figure 1

MDPI and ACS Style

Lee, Y.-T.; Chuang, Y.-M.; Chan, M.W.Y. Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review. Epigenomes 2020, 4, 27. https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes4040027

AMA Style

Lee Y-T, Chuang Y-M, Chan MWY. Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review. Epigenomes. 2020; 4(4):27. https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes4040027

Chicago/Turabian Style

Lee, Yu-Ting; Chuang, Yu-Ming; Chan, Michael W.Y. 2020. "Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review" Epigenomes 4, no. 4: 27. https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes4040027

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop